QCG
FLNA

Quadrant Capital Group’s Filana Therapeutics FLNA Stock Holding History

Quadrant Capital Group’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-98
Closed -$1.21K – 2785
2024
Q2 		$1.21K Hold
98
– – ﹤0.01% 2541
2024
Q1 		$1.99K Hold
98
– – ﹤0.01% 2512
2023
Q4 		$2.21K Buy
+98
New +$2.07K ﹤0.01% 2459
2023
Q2 		– Sell
-6
Closed -$145 – 2759
2023
Q1 		$145 Buy
+6
New +$166 ﹤0.01% 2692
2022
Q3 		– Sell
-59
Closed -$2K – 2787
2022
Q2 		$2K Buy
+59
New +$1.49K ﹤0.01% 2273

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TI
Tidal Investments Milwaukee, Wisconsin $47.4B AUM 59.58% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Quadrant Capital Group's FLNA Position: Q3 2024 in Review

Quadrant Capital Group sold out of Filana Therapeutics (FLNA) in Q3 2024, closing a stake of 98 shares — an estimated $1.21K sold.

Quadrant Capital Group first reported a position in FLNA in Q2 2022 and held it in 5 quarters. The position peaked at $2.21K in Q4 2023. 161 funds tracked by Wall St. Rank hold FLNA as of Q3 2024.

  • Quadrant Capital Group reported no remaining Filana Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 98 Filana Therapeutics shares in Q3 2024, an estimated $1.21K.
  • Quadrant Capital Group first reported a position in Filana Therapeutics in Q2 2022 and held it in 5 quarters.
  • Quadrant Capital Group's Filana Therapeutics position peaked at $2.21K in Q4 2023.
  • 161 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2024.

Based on Quadrant Capital Group's 13F filing for Q3 2024, filed 12 Nov 2024.